Matching articles for "Pneumovax 23"

Expanded Table: Some Vaccines for Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • October 17, 2022;  (Issue 1661)
...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e170-3 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • June 1, 2014;  (Issue 142)
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on...
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately.

Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
Treat Guidel Med Lett. 2014 Jun;12(142):39-48 | Show Full IntroductionHide Full Introduction

Pneumococcal Vaccine for Adults

   
The Medical Letter on Drugs and Therapeutics • October 29, 2012;  (Issue 1402)
The US Advisory Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13), even if they...
The US Advisory Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13), even if they have already received the older 23-valent unconjugated vaccine (PPSV23; Pneumovax 23). Prevnar 13, initially approved by the FDA for use in infants and young children, has been licensed since December 2011 for adults ≥50 years old.
Med Lett Drugs Ther. 2012 Oct 29;54(1402):87-8 | Show Full IntroductionHide Full Introduction

Adult Immunizations

   
The Medical Letter on Drugs and Therapeutics • December 1, 2011;  (Issue 112)
Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed...
Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.
Treat Guidel Med Lett. 2011 Dec;9(112):75-82 | Show Full IntroductionHide Full Introduction

An Expanded Pneumococcal Vaccine (Prevnar 13) for Infants and Children

   
The Medical Letter on Drugs and Therapeutics • August 23, 2010;  (Issue 1345)
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for the prevention of invasive pneumococcal disease (IPD) in infants and children...
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces Prevnar (PCV7). An unconjugated 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 – Merck) is FDA-approved for use in adults.
Med Lett Drugs Ther. 2010 Aug 23;52(1345):67-8 | Show Full IntroductionHide Full Introduction

Pneumococcal Vaccination of Adults: Polysaccharide or Conjugate?

   
The Medical Letter on Drugs and Therapeutics • June 15, 2009;  (Issue 1314)
A 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 - Merck) is the only pneumococcal vaccine approved for use in adults. It has reduced the risk of invasive pneumococcal disease (meningitis or bacteremic...
A 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 - Merck) is the only pneumococcal vaccine approved for use in adults. It has reduced the risk of invasive pneumococcal disease (meningitis or bacteremic pneumonia), but not mortality, in immunocompetent older adults.2 PPSV23 has not been shown to reduce the risk of invasive pneumococcal disease (IPD) in immunocompromised patients.

Click here to view the free full article.
Med Lett Drugs Ther. 2009 Jun 15;51(1314):47-8 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • April 1, 2009;  (Issue 80)
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed...
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Vaccines for travel are reviewed separately.
Treat Guidel Med Lett. 2009 Apr;7(80):27-36 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • July 1, 2006;  (Issue 47)
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed...
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Immunizations for travel were reviewed in a recent issue.
Treat Guidel Med Lett. 2006 Jul;4(47):47-54 | Show Full IntroductionHide Full Introduction

A Pneumococcal Conjugate Vaccine for Infants and Children

   
The Medical Letter on Drugs and Therapeutics • March 20, 2000;  (Issue 1074)
The FDA has approved a conjugate heptavalent pneumococcal vaccine for prevention of invasive pneumococcal disease in infants and...
The FDA has approved a conjugate heptavalent pneumococcal vaccine for prevention of invasive pneumococcal disease in infants and children.
Med Lett Drugs Ther. 2000 Mar 20;42(1074):25-7 | Show Full IntroductionHide Full Introduction

Pneumococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • September 10, 1999;  (Issue 1061)
Increased resistance of pneumococci to antimicrobial drugs may encourage more extensive use of pneumococcal polysaccharide...
Increased resistance of pneumococci to antimicrobial drugs may encourage more extensive use of pneumococcal polysaccharide vaccine.
Med Lett Drugs Ther. 1999 Sep 10;41(1061):84 | Show Full IntroductionHide Full Introduction